公开(公告)号：US20160002173A1

公开(公告)日：2016-01-07

申请号：US14772540

申请日：2014-03-12

Applicant: CEPHALON, INC.

Inventor： Peter D. BROWN ,  Anthony S. DRAGER

IPC: C07D235/16 ,  A61K9/50 ,  A61K31/4184

CPC classification number: A61K9/5146 ,  A61K9/145 ,  A61K9/5031 ,  A61K9/5089 ,  A61K31/4184 ,  A61K31/7088 ,  A61K38/02 ,  A61K47/60 ,  A61K47/6935 ,  C07D235/16

Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.

Abstract translation: 本发明涉及通过至少一种表面活性剂和含异氰酸酯的化合物的聚合制备的颗粒。 还描述了使用这些颗粒制备的药物组合物。

公开(公告)号：US20160001957A1

公开(公告)日：2016-01-07

申请号：US14849719

申请日：2015-09-10

Applicant: Cephalon, Inc.

Inventor： Randy J. Bradway ,  Gerald A. Frank

IPC: B65D83/04 ,  A61K31/485 ,  A61K31/4468 ,  A61J1/03

CPC classification number: B65D83/0409 ,  A61J1/03 ,  A61J7/003 ,  A61J7/0053 ,  A61K31/4468 ,  A61K31/485 ,  A61M31/007

Abstract: A child resistant safety device for an oral dosage form including a handle having a proximal end and a distal end to which an oral dosage form is mounted either directly or indirectly; a cover that moves with respect to the handle, or vice versa, for selectively shielding the oral dosage form; and a releasable locking mechanism that is moveable between a locked configuration and an unlocked configuration. In the locked configuration, the releasable locking mechanism is configured to prevent movement of the safety device to a deployed configuration in which the oral dosage form is exposed, and, in the unlocked configuration, the releasable locking mechanism is configured to permit movement of the safety device to the deployed configuration.

Abstract translation: 用于口服剂型的耐儿童安全装置，包括具有直接或间接安装口服剂型的近端和远端的手柄; 相对于手柄移动的盖子，反之亦然，用于选择性地屏蔽口服剂型; 以及可在锁定配置和解锁配置之间移动的可释放锁定机构。 在锁定构造中，可释放锁定机构构造成防止安全装置移动到其中暴露出口服剂型的展开构型，并且在解锁构造中，可释放锁定机构构造成允许安全 设备到部署配置。

公开(公告)号：US20150335750A1

公开(公告)日：2015-11-26

申请号：US14814570

申请日：2015-07-31

Applicant: Cephalon, Inc.

Inventor： Anthony S. Drager ,  Rachel Y. LaBell ,  Piyush R. Patel

IPC: A61K47/10 ,  A61K9/00 ,  A61K31/4184

CPC classification number: A61K31/4184 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/40

Abstract: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.

Abstract translation: 描述了苯达莫司汀及其药学上可接受的盐和极性非质子溶剂的稳定液体制剂。

公开(公告)号：US08883836B2

公开(公告)日：2014-11-11

申请号：US14200738

申请日：2014-03-07

Applicant: Cephalon, Inc.

Inventor： Martin Ian Cooper ,  Laurent D. Courvoisier ,  Mark Eddleston ,  Robert E. McKean

IPC: C07D235/16

CPC classification number: A61K31/4184 ,  A61K9/0019 ,  A61K9/14 ,  A61K9/19 ,  A61K47/26 ,  C07D235/16

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Abstract translation: 描述了新型固体形式的盐酸苯达莫司汀，以及它们的制备和使用方法。

公开(公告)号：US20140187598A1

公开(公告)日：2014-07-03

申请号：US14200738

申请日：2014-03-07

Applicant: Cephalon, Inc.

Inventor： Martin Ian Cooper ,  Laurent D. Courvoisier ,  Mark Eddleston ,  Robert E. McKean

IPC: C07D235/16

CPC classification number: A61K31/4184 ,  A61K9/0019 ,  A61K9/14 ,  A61K9/19 ,  A61K47/26 ,  C07D235/16

Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.

Abstract translation: 描述了新型固体形式的盐酸苯达莫司汀，以及它们的制备和使用方法。

公开(公告)号：US20130123499A1

公开(公告)日：2013-05-16

申请号：US13678886

申请日：2012-11-16

Applicant: Cephalon, Inc. ,  Cephalon France

Inventor： Shawn P. Allwein ,  Arnaud Grandeury ,  Guy Piacenza ,  Sebastien Rose

IPC: C07D487/14

CPC classification number: C07D487/14

Abstract: The present invention relates a method for purifying a fused pyrrolocarbazole compound known as 11-isobutyl-2-methyl-8-(2-pyrimidinylamino)-2,5,6,11,12,13-hexahydro-4Hindazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one using an acid complex thereof. The present invention also relates to a crystalline form of the acid complex.

Abstract translation: 本发明涉及一种纯化称为11-异丁基-2-甲基-8-（2-嘧啶基氨基）-2,5,6,11,12,13-六氢-4H-吲唑并[5,4-噻唑并[ a]吡咯并[3,4-c]咔唑-4-酮。 本发明还涉及酸络合物的结晶形式。

公开(公告)号：US20130072562A1

公开(公告)日：2013-03-21

申请号：US13654765

申请日：2012-10-18

Applicant: The Trustees Of The University Of Pennsyvania ,  Cephalon, Inc.

Inventor： MARK I. GREENE ,  RAMACHANDRAN MURALI ,  XIN CHENG ,  RAPHAEL OTTENBRITE ,  YINGXIN XIAO

IPC: C07C251/86

CPC classification number: C07D493/10 ,  A61K31/15 ,  A61K31/352 ,  A61K31/365 ,  C07C251/86 ,  C07D311/82

Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions.

Abstract translation: 本发明涉及作为肿瘤坏死因子受体I的变构抑制剂的化合物，包含这些化合物的组合物，以及使用这些化合物及其组合物治疗TNF-α介导的病症的方法。

公开(公告)号：US20040102609A1

公开(公告)日：2004-05-27

申请号：US10685923

申请日：2003-10-14

Applicant: Cephalon Inc.

Inventor： Sankar Chatterjee ,  John P. Mallamo ,  Ron Bihovsky ,  Gregory J. Wells

IPC: C07K005/06 ,  C07K005/04

CPC classification number: C07D207/08 ,  C07C311/06 ,  C07C311/46 ,  C07C311/48 ,  C07D207/20 ,  C07D207/48 ,  C07D211/76 ,  C07D211/96 ,  C07D213/70 ,  C07D213/74 ,  C07D235/06 ,  C07D239/42 ,  C07D275/06 ,  C07D277/40 ,  C07D277/54 ,  C07D333/34 ,  C07D333/62 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07K5/0202 ,  C07K5/06069

Abstract: This invention relates to peptide-containing null-ketoamide inhibitors of cysteine and serine proteases, methods for making these compounds, and methods for using the same.

Abstract translation: 本发明涉及半胱氨酸和丝氨酸蛋白酶的含肽α-酮酰胺抑制剂，制备这些化合物的方法及其使用方法。

公开(公告)号：US20020169154A1

公开(公告)日：2002-11-14

申请号：US10115407

申请日：2002-04-03

Applicant: Cephalon, Inc.

Inventor： Bruce A. Ruggeri ,  Susan E. Jones-Bolin

IPC: A61K031/553

CPC classification number: A61K45/06 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/52 ,  A61K31/553 ,  A61K31/7068 ,  A61K2300/00

Abstract: Novel methods and compositions comprising antineoplastic agents and trk tyrosine kinase inhibitors are disclosed. In preferred embodiments, the antineoplastic agents comprise nucleoside analogs, and the trk tyrosine kinase inhibitors comprise indolocarbazoles and indenocarbazoles. The methods and compositions may be suitable for the treatment of cancer, particularly pancreatic cancer.

Abstract translation: 公开了包含抗肿瘤剂和trk酪氨酸激酶抑制剂的新方法和组合物。 在优选的实施方案中，抗肿瘤剂包括核苷类似物，并且trk酪氨酸激酶抑制剂包含吲哚并唑和茚啶咔唑。 所述方法和组合物可适用于治疗癌症，特别是胰腺癌。

公开(公告)号：US20020147341A1

公开(公告)日：2002-10-10

申请号：US10062159

申请日：2002-02-01

Applicant: Cephalon, Inc.

Inventor： Robert L. Hudkins

IPC: C07D498/14 ,  C07D471/14 ,  A61K031/407

CPC classification number: C07D471/14 ,  C07D487/04 ,  C07D491/14 ,  C07D495/14

Abstract: The present invention is directed to novel fused pyrrolocarbazoles and isoindolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.